|
OCTOBER 20, 2023
Threat of Fungal Infections And Need for New Drugs Are Still Acute
By Myles Starr
Nearly three years after the FDA convened experts for a public workshop to address the unmet need for antifungal agents, the antifungal pipeline remains small due to a host of hurdles.
Infectious Disease Special Edition spoke with several experts who presented at the FDA workshop to see where progress has—and has not—been made in addressing the dearth of effective antifungal agents.
“Although numbers of serious fungal infections are increasing slightly, the main concern at the moment is not the growing number of serious or lethal fungal infections in the U.S., but the fact that resistance to the limited number of drugs we have at our disposal is emerging. There is a lack of new treatments being approved or in the pipeline,” said Peter G. Pappas, MD, FACP, the William E. Dismukes Professor of Medicine, Mycoses Study Group Division of Infectious Diseases at the University of Alabama at Birmingham.
Continue reading... https://www.idse.net/Fungal-Infection/Article/10-23/Threat-of-Fungal-Infections-And-Need-for-New-Drugs-Are-Still-Acute/71643
"Reproduced with permission - Infectious Disease Special Edition (IDSE)"
Infectious Disease Special Edition (IDSE)
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News |
